<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	 xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>Shop &#8211; BEHEMOTH LABZ</title>
	<atom:link href="https://behemothlabz.com/shop/feed/" rel="self" type="application/rss+xml" />
	<link>https://behemothlabz.com</link>
	<description>For all your Laboratory research needs</description>
	<lastBuildDate>Mon, 19 Oct 2026 15:38:39 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://behemothlabz.com/wp-content/uploads/2024/11/cropped-favi-1-01-32x32.png</url>
	<title>Shop &#8211; BEHEMOTH LABZ</title>
	<link>https://behemothlabz.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Ezetimibe</title>
		<link>https://behemothlabz.com/product/ezetimibe/</link>
		
		<dc:creator><![CDATA[Zeeshan Tariq]]></dc:creator>
		<pubDate>Mon, 19 Oct 2026 14:37:42 +0000</pubDate>
				<guid isPermaLink="false">https://behemothlabz.com/?post_type=product&#038;p=150876</guid>

					<description><![CDATA[Buy Ezetimibe Online Ezetimibe is a prescription medication used to lower elevated LDL cholesterol. It works differently from statins by reducing the absorption of cholesterol in the small intestine. It may be prescribed alone in selected cases or alongside a statin when additional LDL reduction is needed. Product Information Ezetimibe is available as an oral [...]]]></description>
										<content:encoded><![CDATA[<h2><b>Buy Ezetimibe Online</b></h2>
<p><span style="font-weight: 400;">Ezetimibe is a prescription medication used to lower elevated LDL cholesterol. It works differently from statins by reducing the absorption of cholesterol in the small intestine. It may be prescribed alone in selected cases or alongside a statin when additional LDL reduction is needed.</span></p>
<h2><b>Product Information</b></h2>
<p><span style="font-weight: 400;">Ezetimibe is available as an oral tablet, commonly in a 10 mg strength. It may be used alone or in combination with certain statins and other lipid-lowering treatments, depending on the patient's condition and the relevant product label. Its role is to support cholesterol management alongside dietary measures and an individualized cardiovascular risk-reduction plan.</span></p>
<h2><b>How It Works</b></h2>
<p><span style="font-weight: 400;">Ezetimibe inhibits the NPC1L1 cholesterol-transport protein at the intestinal brush border, reducing the absorption of dietary and biliary cholesterol. This lowers the amount of cholesterol delivered to the liver and encourages increased clearance of LDL cholesterol from the bloodstream.</span></p>
<h2><b>POTENTIAL BENEFITS</b></h2>
<h3><b>1. Helps Lower LDL Cholesterol</b></h3>
<p><span style="font-weight: 400;">Ezetimibe reduces LDL cholesterol by limiting intestinal cholesterol absorption. It can be useful for people who need additional LDL lowering or for whom statin treatment alone is not appropriate or sufficient.</span></p>
<h3><b>2. Complements Statin Therapy</b></h3>
<p><span style="font-weight: 400;">Because ezetimibe acts through a different mechanism from statins, combining the two can provide additional LDL reduction. The combination may be considered when a person's cholesterol remains above their treatment target despite an appropriate statin regimen.</span></p>
<h3><b>3. Provides an Alternative Mechanism for Cholesterol Management</b></h3>
<p><span style="font-weight: 400;">Ezetimibe offers a non-statin approach to reducing cholesterol absorption. For selected patients who cannot tolerate a statin or need a different treatment strategy, it can be considered by a clinician based on their risk profile and lipid results.</span></p>
<h3><b>4. Supports Management of Inherited High Cholesterol</b></h3>
<p><span style="font-weight: 400;">Ezetimibe can be used as part of treatment for certain forms of primary hyperlipidemia, including heterozygous familial hypercholesterolemia. In these cases, it may be combined with other therapies to help achieve an appropriate LDL reduction.</span></p>
<h2><b>Dosage</b></h2>
<p><span style="font-weight: 400;">The standard labeled adult dose is <b>10 mg orally once daily</b>, with or without food. If a bile acid sequestrant is also prescribed, ezetimibe should be taken at least 2 hours before or 4 hours after that medication. When used with a statin or other lipid-lowering therapy, the other medication's prescribing instructions and monitoring requirements also apply. Treatment should be guided by a healthcare professional.</span></p>
<h2><b>Side Effects</b></h2>
<p><span style="font-weight: 400;">Ezetimibe is generally well tolerated, but possible side effects include upper respiratory symptoms, diarrhea, joint pain, and muscle aches. When used with a statin, the combination may increase the need to assess unexplained muscle symptoms or liver enzyme changes. Patients with liver disease or those taking other cholesterol medications should discuss appropriate monitoring with their prescriber.</span></p>
<h3><b>References</b></h3>
<ol>
<li style="font-weight: 400;"><a href="https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=11de499b-ad8a-46a6-9021-c8eba72ae414" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">DailyMed — Ezetimibe Tablets: Official Prescribing Information</span></a></li>
<li style="font-weight: 400;"><a href="https://medlineplus.gov/druginfo/meds/a603015.html" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">MedlinePlus — Ezetimibe Drug Information</span></a></li>
</ol>
<p><b>Note:</b><span style="font-weight: 400;"> BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.</span></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Doxazosin</title>
		<link>https://behemothlabz.com/product/doxazosin/</link>
		
		<dc:creator><![CDATA[Zeeshan Tariq]]></dc:creator>
		<pubDate>Mon, 19 Oct 2026 14:37:30 +0000</pubDate>
				<guid isPermaLink="false">https://behemothlabz.com/?post_type=product&#038;p=150874</guid>

					<description><![CDATA[Buy Doxazosin Online Doxazosin is a prescription alpha-1 blocker used to relieve urinary symptoms associated with benign prostatic hyperplasia (BPH). Immediate-release doxazosin is also indicated for hypertension in some markets and product labels. The intended use matters because the available formulations and recommended regimens differ. Product Information Doxazosin is commonly supplied as oral tablets containing [...]]]></description>
										<content:encoded><![CDATA[<h2><b>Buy Doxazosin Online</b></h2>
<p><span style="font-weight: 400;">Doxazosin is a prescription alpha-1 blocker used to relieve urinary symptoms associated with benign prostatic hyperplasia (BPH). Immediate-release doxazosin is also indicated for hypertension in some markets and product labels. The intended use matters because the available formulations and recommended regimens differ.</span></p>
<h2><b>Product Information</b></h2>
<p><span style="font-weight: 400;">Doxazosin is commonly supplied as oral tablets containing doxazosin mesylate. Immediate-release tablets are available in 1 mg, 2 mg, 4 mg, and 8 mg strengths. An extended-release formulation is also available in certain markets for BPH. Extended-release and immediate-release products should not be treated as interchangeable without clinical guidance.</span></p>
<h2><b>How It Works</b></h2>
<p><span style="font-weight: 400;">Doxazosin selectively blocks alpha-1 adrenergic receptors in vascular smooth muscle and, in BPH, in the smooth muscle of the prostate and bladder neck. This relaxes blood vessels and can reduce vascular resistance. Relaxation of smooth muscle around the urinary outlet can improve urine flow and relieve certain lower urinary tract symptoms.</span></p>
<h2><b>POTENTIAL BENEFITS</b></h2>
<h3><b>1. Helps Relieve BPH-Related Urinary Symptoms</b></h3>
<p><span style="font-weight: 400;">Doxazosin can improve symptoms associated with an enlarged prostate, including a weak urine stream, difficulty starting urination, and the sensation of incomplete bladder emptying. It eases smooth-muscle tension but does not shrink the prostate itself.</span></p>
<h3><b>2. Supports Improved Urine Flow</b></h3>
<p><span style="font-weight: 400;">By relaxing smooth muscle around the bladder outlet and prostate, doxazosin can reduce resistance to urine flow. The degree of improvement varies, and persistent or worsening urinary symptoms need assessment to rule out other causes.</span></p>
<h3><b>3. Can Lower Blood Pressure</b></h3>
<p><span style="font-weight: 400;">Immediate-release doxazosin is also used to treat hypertension under appropriate prescribing guidance. By relaxing blood vessels, it can reduce vascular resistance, though it is not necessarily the first medication selected for uncomplicated high blood pressure.</span></p>
<h3><b>4. Offers Formulation Options for BPH Treatment</b></h3>
<p><span style="font-weight: 400;">Immediate-release tablets and extended-release products provide different release characteristics. The appropriate formulation depends on the indication, tolerability, and prescribing instructions, with particular care needed when starting treatment or changing formulations.</span></p>
<h2><b>Dosage</b></h2>
<p><span style="font-weight: 400;">For immediate-release doxazosin in adults, the labeled starting dose is typically <b>1 mg once daily</b>, with gradual titration based on response and tolerability. For BPH, immediate-release doses may be adjusted up to 8 mg daily according to the product label. Extended-release formulations have separate instructions and are intended for BPH rather than general substitution for immediate-release tablets. First-dose dizziness and fainting are important considerations; use only as prescribed.</span></p>
<h2><b>Side Effects</b></h2>
<p><span style="font-weight: 400;">Common side effects include dizziness, fatigue, headache, and low blood pressure, especially when standing. Fainting can occur, particularly after the first dose or a dose increase. Doxazosin may also cause swelling or palpitations. Patients should be cautious when standing up and discuss use with a clinician, particularly if also taking erectile-dysfunction medicines or other blood-pressure-lowering drugs.</span></p>
<h3><b>References</b></h3>
<ol>
<li style="font-weight: 400;"><a href="https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=277c3278-4fe2-47ac-9115-15b417325ffd" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">DailyMed — Doxazosin Tablets: Official Prescribing Information</span></a></li>
<li style="font-weight: 400;"><a href="https://medlineplus.gov/druginfo/meds/a693045.html" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">MedlinePlus — Doxazosin Drug Information</span></a></li>
</ol>
<p><b>Note:</b><span style="font-weight: 400;"> BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.</span></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Propranolol</title>
		<link>https://behemothlabz.com/product/propranolol/</link>
		
		<dc:creator><![CDATA[Zeeshan Tariq]]></dc:creator>
		<pubDate>Mon, 19 Oct 2026 14:37:23 +0000</pubDate>
				<guid isPermaLink="false">https://behemothlabz.com/?post_type=product&#038;p=150872</guid>

					<description><![CDATA[Buy Propranolol Online Propranolol is a prescription beta blocker used for several conditions, including certain heart and blood-pressure disorders, prevention of migraine, and management of specific physical symptoms associated with performance anxiety. Its appropriate use depends on the indication and the formulation prescribed. Product Information Propranolol hydrochloride is available in multiple oral formulations, including immediate-release [...]]]></description>
										<content:encoded><![CDATA[<h2><b>Buy Propranolol Online</b></h2>
<p><span style="font-weight: 400;">Propranolol is a prescription beta blocker used for several conditions, including certain heart and blood-pressure disorders, prevention of migraine, and management of specific physical symptoms associated with performance anxiety. Its appropriate use depends on the indication and the formulation prescribed.</span></p>
<h2><b>Product Information</b></h2>
<p><span style="font-weight: 400;">Propranolol hydrochloride is available in multiple oral formulations, including immediate-release tablets, extended-release capsules, and certain extended-release tablet products. Oral solutions are also available in some markets or for specific clinical needs. Strengths and approved indications differ between products. Immediate-release and extended-release formulations are <b>not automatically interchangeable milligram for milligram</b>.</span></p>
<h2><b>How It Works</b></h2>
<p><span style="font-weight: 400;">Propranolol blocks beta-adrenergic receptors, reducing the effects of adrenaline and related stress hormones on the heart and other tissues. This can slow heart rate, reduce the force of cardiac contraction, and lower blood pressure. Its effects on physical stress responses also explain some of its non-cardiac clinical uses.</span></p>
<h2><b>POTENTIAL BENEFITS</b></h2>
<h3><b>1. Supports Blood Pressure and Heart-Rate Management</b></h3>
<p><span style="font-weight: 400;">Propranolol can help lower heart rate and blood pressure in appropriate patients. It is prescribed for selected cardiovascular conditions, with the specific formulation and regimen determined by the diagnosis and treatment goals.</span></p>
<h3><b>2. Helps Manage Certain Heart Conditions</b></h3>
<p><span style="font-weight: 400;">Depending on the clinical situation, propranolol may be used for conditions such as angina, selected cardiac rhythm disorders, and other indications listed in the relevant product labeling. Treatment requires assessment of heart rate, blood pressure, and any underlying cardiac or respiratory disease.</span></p>
<h3><b>3. Can Help Prevent Migraine</b></h3>
<p><span style="font-weight: 400;">Certain propranolol formulations and regimens are used to reduce the frequency of migraine attacks. Preventive treatment is generally assessed over time, and it does not act as an immediate pain reliever for an attack already underway.</span></p>
<h3><b>4. Reduces Some Physical Symptoms of Performance Anxiety</b></h3>
<p><span style="font-weight: 400;">When prescribed appropriately, propranolol can lessen physical manifestations of situational anxiety, such as a racing heart or tremor. It does not directly address every psychological aspect of anxiety and is not suitable for everyone; the use and timing should be discussed with a clinician.</span></p>
<h2><b>Dosage</b></h2>
<p><span style="font-weight: 400;">Propranolol dosing varies considerably by indication and formulation. Immediate-release products may be prescribed in divided daily doses, while certain extended-release products are designed for once-daily administration. There is no single dose that applies to every use. Follow the exact prescription for the specific product, and do not substitute immediate-release and extended-release forms without professional advice.</span></p>
<h2><b>Side Effects</b></h2>
<p><span style="font-weight: 400;">Common side effects include fatigue, dizziness, cold hands or feet, sleep disturbances, and a slow heart rate. Propranolol may cause low blood pressure and can mask some warning signs of low blood glucose. Because it can constrict airways, it may be unsuitable for people with asthma or certain other respiratory conditions. It should not be stopped abruptly without medical advice, particularly when used for cardiovascular disease.</span></p>
<h3><b>References</b></h3>
<ol>
<li style="font-weight: 400;"><a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=414c4b69-38a1-4220-bec8-204c9a624b85" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">DailyMed — Propranolol Hydrochloride Extended-Release Capsules: Official Prescribing Information</span></a></li>
<li style="font-weight: 400;"><a href="https://medlineplus.gov/druginfo/meds/a682607.html" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">MedlinePlus — Propranolol Drug Information</span></a></li>
</ol>
<p><b>Note:</b><span style="font-weight: 400;"> BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.</span></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Fluvoxamine</title>
		<link>https://behemothlabz.com/product/fluvoxamine/</link>
		
		<dc:creator><![CDATA[Zeeshan Tariq]]></dc:creator>
		<pubDate>Mon, 19 Oct 2026 14:37:16 +0000</pubDate>
				<guid isPermaLink="false">https://behemothlabz.com/?post_type=product&#038;p=150870</guid>

					<description><![CDATA[Buy Fluvoxamine Online Fluvoxamine is a prescription antidepressant primarily used to treat obsessive-compulsive disorder (OCD). It belongs to the selective serotonin reuptake inhibitor (SSRI) class and is available in immediate-release tablets and extended-release capsules, depending on the product and market. Product Information Fluvoxamine maleate is an oral medication. Immediate-release tablets are commonly available in 25 [...]]]></description>
										<content:encoded><![CDATA[<h2><b>Buy Fluvoxamine Online</b></h2>
<p><span style="font-weight: 400;">Fluvoxamine is a prescription antidepressant primarily used to treat obsessive-compulsive disorder (OCD). It belongs to the selective serotonin reuptake inhibitor (SSRI) class and is available in immediate-release tablets and extended-release capsules, depending on the product and market.</span></p>
<h2><b>Product Information</b></h2>
<p><span style="font-weight: 400;">Fluvoxamine maleate is an oral medication. Immediate-release tablets are commonly available in 25 mg, 50 mg, and 100 mg strengths, while extended-release capsules are available in 100 mg and 150 mg strengths. These formulations differ in how the medication is released and how often it is taken. In the United States, its labeled indication includes OCD; approved uses may vary by country.</span></p>
<h2><b>How It Works</b></h2>
<p><span style="font-weight: 400;">Fluvoxamine reduces the reuptake of serotonin, a chemical messenger involved in mood and behavior regulation. This increases serotonin availability between nerve cells and can help reduce OCD symptoms over time. Its clinical effects generally develop gradually rather than immediately.</span></p>
<h2><b>POTENTIAL BENEFITS</b></h2>
<h3><b>1. Helps Reduce Obsessive Thoughts</b></h3>
<p><span style="font-weight: 400;">Fluvoxamine is an established medication for OCD, a condition that can involve persistent, unwanted thoughts or urges. For many patients, treatment can reduce the intensity and frequency of obsessions and make daily routines easier to manage.</span></p>
<h3><b>2. Helps Manage Compulsive Behaviors</b></h3>
<p><span style="font-weight: 400;">By reducing OCD symptom severity, fluvoxamine may help patients spend less time performing repetitive behaviors or mental rituals. It is often used as part of a broader treatment plan that may include cognitive behavioral therapy, particularly exposure and response prevention.</span></p>
<h3><b>3. Supports Long-Term Symptom Management</b></h3>
<p><span style="font-weight: 400;">OCD often requires ongoing care rather than a short course of medication. When effective and well tolerated, fluvoxamine can form part of a sustained treatment plan, with periodic clinical reviews to assess response and determine whether treatment should continue.</span></p>
<h3><b>4. Offers More Than One Oral Formulation</b></h3>
<p><span style="font-weight: 400;">Immediate-release tablets allow dose adjustments using smaller tablet strengths, while extended-release capsules provide a once-daily formulation. The choice depends on the prescribed regimen, tolerability, and individual clinical needs; the formulations should not be switched casually.</span></p>
<h2><b>Dosage</b></h2>
<p><span style="font-weight: 400;">For adults taking immediate-release fluvoxamine tablets for OCD, the labeled starting dose is commonly <b>50 mg daily at bedtime</b>, with gradual increases according to response and tolerability. The usual maximum is 300 mg per day; doses above 100 mg daily are generally divided. Extended-release capsules have a different dosing schedule, so their instructions should be followed separately. Do not start, adjust, or discontinue fluvoxamine without medical guidance.</span></p>
<h2><b>Side Effects</b></h2>
<p><span style="font-weight: 400;">Common side effects include nausea, sleepiness or insomnia, sweating, nervousness, reduced appetite, and sexual dysfunction. Important risks include serotonin syndrome, increased bleeding risk, low blood sodium, mania in susceptible patients, and increased suicidal thoughts or behaviors in some younger patients. Fluvoxamine also has clinically significant drug interactions, so a prescriber or pharmacist should review other medications before treatment.</span></p>
<h3><b>References</b></h3>
<ol>
<li style="font-weight: 400;"><a href="https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=642b7b5e-9f1c-479b-b9b3-bf06774f7b60" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">DailyMed — Fluvoxamine Maleate Tablets: Official Prescribing Information</span></a></li>
<li style="font-weight: 400;"><a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4527a684-51c0-1858-e063-6394a90a2631" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">DailyMed — Fluvoxamine Maleate Extended-Release Capsules: Official Prescribing Information</span></a></li>
<li style="font-weight: 400;"><a href="https://medlineplus.gov/druginfo/meds/a695004.html" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">MedlinePlus — Fluvoxamine Drug Information</span></a></li>
</ol>
<p><b>Note:</b><span style="font-weight: 400;"> BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.</span></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Rosuvastatin</title>
		<link>https://behemothlabz.com/product/rosuvastatin/</link>
		
		<dc:creator><![CDATA[Zeeshan Tariq]]></dc:creator>
		<pubDate>Mon, 19 Oct 2026 14:37:05 +0000</pubDate>
				<guid isPermaLink="false">https://behemothlabz.com/?post_type=product&#038;p=150868</guid>

					<description><![CDATA[Buy Rosuvastatin Online Rosuvastatin is a prescription cholesterol-lowering medication used to manage elevated LDL cholesterol and reduce the risk of serious cardiovascular events in eligible patients. It is commonly prescribed alongside dietary changes and other measures to support long-term heart health. Product Information Rosuvastatin belongs to the statin class of medications. It is available primarily [...]]]></description>
										<content:encoded><![CDATA[<h2><b>Buy Rosuvastatin Online</b></h2>
<p><span style="font-weight: 400;">Rosuvastatin is a prescription cholesterol-lowering medication used to manage elevated LDL cholesterol and reduce the risk of serious cardiovascular events in eligible patients. It is commonly prescribed alongside dietary changes and other measures to support long-term heart health.</span></p>
<h2><b>Product Information</b></h2>
<p><span style="font-weight: 400;">Rosuvastatin belongs to the statin class of medications. It is available primarily as oral film-coated tablets, commonly in 5 mg, 10 mg, 20 mg, and 40 mg strengths. The appropriate strength depends on cholesterol levels, cardiovascular risk, treatment goals, other medications, and individual tolerability.</span></p>
<h2><b>How It Works</b></h2>
<p><span style="font-weight: 400;">Rosuvastatin inhibits HMG-CoA reductase, an enzyme involved in cholesterol production in the liver. This prompts the liver to increase its uptake of LDL cholesterol from the bloodstream, helping lower circulating LDL and total cholesterol.</span></p>
<h2><b>POTENTIAL BENEFITS</b></h2>
<h3><b>1. Helps Lower LDL Cholesterol</b></h3>
<p><span style="font-weight: 400;">Rosuvastatin can substantially reduce low-density lipoprotein (LDL), commonly called “bad” cholesterol. Lowering LDL is an important part of managing elevated cholesterol and reducing the long-term burden of atherosclerotic cardiovascular disease.</span></p>
<h3><b>2. Supports Cardiovascular Risk Reduction</b></h3>
<p><span style="font-weight: 400;">For appropriately selected patients, rosuvastatin helps reduce the risk of major cardiovascular events, including heart attack and stroke. The benefit depends on the person's baseline risk, treatment intensity, and adherence to the prescribed regimen.</span></p>
<h3><b>3. Helps Manage Inherited High Cholesterol</b></h3>
<p><span style="font-weight: 400;">Rosuvastatin is used in certain patients with familial hypercholesterolemia, an inherited condition associated with elevated LDL cholesterol. Treatment can help improve lipid levels alongside dietary management and other therapies when required.</span></p>
<h3><b>4. Improves the Overall Lipid Profile</b></h3>
<p><span style="font-weight: 400;">In addition to lowering LDL cholesterol, rosuvastatin can reduce total cholesterol and triglycerides while modestly increasing HDL cholesterol in some patients. The magnitude of these changes varies with dose and individual response.</span></p>
<h2><b>Dosage</b></h2>
<p><span style="font-weight: 400;">For adults, labeled rosuvastatin tablet doses generally range from <b>5 mg to 40 mg once daily</b>. The starting dose and subsequent adjustments depend on the treatment indication, LDL response, kidney function, ancestry-related prescribing considerations, and potential drug interactions. Higher doses may increase the risk of muscle-related adverse effects. This is a prescription medication; dosing should be determined by a qualified healthcare professional.</span></p>
<h2><b>Side Effects</b></h2>
<p><span style="font-weight: 400;">Commonly reported side effects include headache, nausea, muscle aches, abdominal discomfort, and weakness. More serious risks include myopathy, rare rhabdomyolysis, liver enzyme elevations, and increased blood glucose in susceptible patients. New or unexplained muscle pain, marked weakness, or dark urine warrants prompt medical assessment. Pregnancy, breastfeeding, kidney problems, and interacting medicines require specific clinical consideration.</span></p>
<h3><b>References</b></h3>
<ol>
<li style="font-weight: 400;"><a href="https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf40166a-4f73-47ff-938b-2bdbf7f000e4" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">DailyMed — Rosuvastatin Calcium Tablets: Official Prescribing Information</span></a></li>
<li style="font-weight: 400;"><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021366" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">FDA — Crestor (Rosuvastatin) Prescribing Information and Drug Information</span></a></li>
</ol>
<p><b>Note:</b><span style="font-weight: 400;"> BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.</span></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Adalank</title>
		<link>https://behemothlabz.com/product/adalank/</link>
		
		<dc:creator><![CDATA[Zeeshan Tariq]]></dc:creator>
		<pubDate>Thu, 01 Oct 2026 17:05:45 +0000</pubDate>
				<guid isPermaLink="false">https://behemothlabz.com/?post_type=product&#038;p=150786</guid>

					<description><![CDATA[Adalank is marketed as a stabilized or modified analogue of Selank, a synthetic peptide originally investigated for anxiolytic and neuroactive effects. However, the public scientific record for Adalank itself is extremely limited, and claims about its properties are largely extrapolated from Selank rather than supported by dedicated Adalank studies.]]></description>
										<content:encoded><![CDATA[<h2><b>Buy Adalank Online</b></h2>
<p><span style="font-weight: 400;">Adalank is marketed as a <b>stabilized or modified analogue of Selank</b>, a synthetic peptide originally investigated for anxiolytic and neuroactive effects. However, the public scientific record for Adalank itself is extremely limited, and claims about its properties are largely extrapolated from Selank rather than supported by dedicated Adalank studies.</span></p>
<h2><b>Product Information</b></h2>
<p><span style="font-weight: 400;">Unlike Selank, which has a defined peptide sequence and a published research record, Adalank does not currently have a clearly documented independent sequence, pharmacokinetic profile, or clinical-trial literature under that name. A 2026 database review reported <b>no PubMed records specifically indexed under “Adalank.”</b></span></p>
<h2><b>How It Works</b></h2>
<p><span style="font-weight: 400;">A validated mechanism for Adalank has not been established. Proposed mechanisms are generally borrowed from Selank research, including potential effects on neurotrophic and neurotransmitter-related pathways, but these mechanisms should not be assumed to apply identically to an analogue whose structure has not been independently characterized.</span></p>
<h2><b>POTENTIAL BENEFITS</b></h2>
<h3><b>1. Selank-Analogue Research</b></h3>
<p><span style="font-weight: 400;">Adalank is primarily relevant to research examining whether structural modification of Selank can alter stability, duration, or biological activity. This is currently a proposed research rationale rather than a clinically demonstrated advantage.</span></p>
<h3><b>2. Neurotrophic Research</b></h3>
<p><span style="font-weight: 400;">Selank research has investigated neurotrophin-related signaling, including BDNF pathways. These findings provide background for Adalank research, but direct evidence for Adalank itself remains limited.</span></p>
<h3><b>3. Cognitive Research</b></h3>
<p><span style="font-weight: 400;">Modified Selank analogues are of interest in research into attention, memory, stress response, and cognitive signaling. However, these areas remain substantially better documented for Selank than for Adalank.</span></p>
<h3><b>4. Peptide-Stability Research</b></h3>
<p><span style="font-weight: 400;">The primary claimed distinction of Adalank is improved stability compared with Selank. Because independent stability studies are not publicly established, this remains an important area for future characterization.</span></p>
<h2><b>Dosage</b></h2>
<p><span style="font-weight: 400;">There is <b>no established human dosage for Adalank</b>. Some commercial sources publish microgram-level protocols, but these are vendor claims rather than validated clinical dosing data. The absence of dedicated human trials means Selank dosing should not simply be transferred to Adalank.</span></p>
<h2><b>Side Effects</b></h2>
<p><span style="font-weight: 400;">A reliable human safety profile has not been established for Adalank. The lack of dedicated clinical studies means its tolerability, pharmacokinetics, metabolism, and long-term effects remain uncertain.</span></p>
<h3><b>References</b></h3>
<ol>
<li style="font-weight: 400;"><a href="https://condorresearch.com/research/what-is-adalank/" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Adalank — literature and PubMed evidence review</span></a></li>
<li style="font-weight: 400;"><a href="https://www.peptisciences.com/protocols/adalank" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Adalank commercial research profile and claimed protocols</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Selank+peptide" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Selank research — PubMed</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Selank+BDNF" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Selank and neurotrophic-factor research — PubMed</span></a></li>
</ol>
<p><b>Note:</b><span style="font-weight: 400;"> BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.</span></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cagrilintide + Semaglutide (CagriSema)</title>
		<link>https://behemothlabz.com/product/cagrilintide-semaglutide-cagrisema/</link>
		
		<dc:creator><![CDATA[Zeeshan Tariq]]></dc:creator>
		<pubDate>Thu, 01 Oct 2026 17:05:42 +0000</pubDate>
				<guid isPermaLink="false">https://behemothlabz.com/?post_type=product&#038;p=150785</guid>

					<description><![CDATA[CagriSema combines cagrilintide, an amylin analogue, with semaglutide, a GLP-1 receptor agonist. The combination is designed to influence complementary pathways involved in appetite, glucose regulation, and body-weight control.]]></description>
										<content:encoded><![CDATA[<h2><b>Buy Cagrilintide + Semaglutide (CagriSema) Online</b></h2>
<p><span style="font-weight: 400;">CagriSema combines <b>cagrilintide</b>, an amylin analogue, with <b>semaglutide</b>, a GLP-1 receptor agonist. The combination is designed to influence complementary pathways involved in appetite, glucose regulation, and body-weight control.</span></p>
<h2><b>Product Information</b></h2>
<p><span style="font-weight: 400;">Cagrilintide acts on amylin receptors, while semaglutide activates GLP-1 receptors. Clinical development has evaluated the two compounds as a once-weekly fixed-dose combination, including phase 3 studies in obesity and type 2 diabetes.</span></p>
<h2><b>How It Works</b></h2>
<p><span style="font-weight: 400;">Semaglutide activates GLP-1 receptors involved in appetite and glucose regulation, while cagrilintide mimics amylin signaling involved in satiety and post-meal metabolic control. Their complementary mechanisms are intended to produce combined effects on energy intake and glucose metabolism.</span></p>
<h2><b>POTENTIAL BENEFITS</b></h2>
<h3><b>1. Weight-Management Research</b></h3>
<p><span style="font-weight: 400;">Phase 3 clinical research has demonstrated substantial body-weight reductions with once-weekly CagriSema. In REIMAGINE 1, the 2.4 mg + 2.4 mg combination produced a mean relative body-weight reduction of 13.8% at week 40 in adults with early-stage type 2 diabetes.</span></p>
<h3><b>2. Glycemic-Control Research</b></h3>
<p><span style="font-weight: 400;">CagriSema has been evaluated in people with type 2 diabetes, including participants receiving basal insulin. Recent phase 3 research demonstrated improved HbA1c compared with placebo and relevant comparator groups.</span></p>
<h3><b>3. Appetite &amp; Satiety Research</b></h3>
<p><span style="font-weight: 400;">GLP-1 and amylin signaling both influence food intake and satiety. Combining these pathways provides a research model for studying multiple physiological signals controlling energy consumption.</span></p>
<h3><b>4. Dual-Pathway Metabolic Research</b></h3>
<p><span style="font-weight: 400;">CagriSema is particularly relevant to research examining whether complementary incretin and amylin signaling can produce broader metabolic effects than either pathway alone.</span></p>
<h2><b>Dosage</b></h2>
<p><span style="font-weight: 400;">Clinical trials have evaluated CagriSema using <b>1.0 mg + 1.0 mg</b> and <b>2.4 mg + 2.4 mg</b> weekly target doses, with dose escalation used during treatment. These are investigational trial regimens and should not be treated as an established general-use dosing protocol.</span></p>
<h2><b>Side Effects</b></h2>
<p><span style="font-weight: 400;">Gastrointestinal adverse events are among the most frequently reported effects in clinical studies. Recent phase 3 research reported nausea and other gastrointestinal disorders among the most common adverse events, consistent with the pharmacology of GLP-1 receptor agonism and previous cagrilintide data.</span></p>
<h3><b>References</b></h3>
<ol>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/42251859/" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">REIMAGINE 2 — Cagrilintide-semaglutide phase 3 trial, PubMed</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/42251856/" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">REIMAGINE 3 — Cagrilintide-semaglutide phase 3 trial, PubMed</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/42251860/" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">REIMAGINE 1 — Cagrilintide-semaglutide phase 3a trial, PubMed</span></a></li>
<li style="font-weight: 400;"><a href="https://clinicaltrials.gov/study/NCT05669755" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">CagriSema cardiovascular outcomes study — ClinicalTrials.gov</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=cagrilintide+amylin+receptor" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Cagrilintide and amylin-receptor research — PubMed</span></a></li>
</ol>
<p><b>Note:</b><span style="font-weight: 400;"> BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.</span></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Tirzepatide</title>
		<link>https://behemothlabz.com/product/tirzepatide/</link>
		
		<dc:creator><![CDATA[Zeeshan Tariq]]></dc:creator>
		<pubDate>Thu, 01 Oct 2026 17:05:39 +0000</pubDate>
				<guid isPermaLink="false">https://behemothlabz.com/?post_type=product&#038;p=150784</guid>

					<description><![CDATA[Tirzepatide is a long-acting GIP and GLP-1 receptor agonist developed for metabolic disease. It has extensive clinical evidence in type 2 diabetes and obesity and is marketed in the United States as Mounjaro and Zepbound for different indications.]]></description>
										<content:encoded><![CDATA[<h2><b>Buy Tirzepatide Online</b></h2>
<p><span style="font-weight: 400;">Tirzepatide is a long-acting <b>GIP and GLP-1 receptor agonist</b> developed for metabolic disease. It has extensive clinical evidence in type 2 diabetes and obesity and is marketed in the United States as Mounjaro and Zepbound for different indications.</span></p>
<h2><b>Product Information</b></h2>
<p><span style="font-weight: 400;">Tirzepatide is a modified peptide engineered for prolonged activity after once-weekly administration. Its dual incretin mechanism combines GIP receptor activation with GLP-1 receptor activation, affecting insulin secretion, glucagon regulation, appetite, and energy balance.</span></p>
<h2><b>How It Works</b></h2>
<p><span style="font-weight: 400;">Tirzepatide activates both GIP and GLP-1 receptors. These pathways enhance glucose-dependent insulin secretion and influence appetite and energy intake, while the combined signaling produces broad metabolic effects.</span></p>
<h2><b>POTENTIAL BENEFITS</b></h2>
<h3><b>1. Blood-Glucose Research</b></h3>
<p><span style="font-weight: 400;">Tirzepatide produces substantial reductions in HbA1c in clinical trials involving type 2 diabetes. Its dual incretin activity contributes to improved glucose regulation.</span></p>
<h3><b>2. Weight-Management Research</b></h3>
<p><span style="font-weight: 400;">Large clinical studies have demonstrated significant body-weight reductions in adults with obesity or overweight. This has made tirzepatide a major subject of modern metabolic research.</span></p>
<h3><b>3. Insulin-Sensitivity Research</b></h3>
<p><span style="font-weight: 400;">GIP and GLP-1 signaling influence insulin secretion and metabolic regulation. Tirzepatide has therefore been investigated extensively for changes in insulin sensitivity and broader cardiometabolic markers.</span></p>
<h3><b>4. Metabolic-Disease Research</b></h3>
<p><span style="font-weight: 400;">Tirzepatide research extends beyond glucose and body weight into cardiovascular risk factors, fatty liver disease, sleep apnea, and other obesity-associated conditions.</span></p>
<h2><b>Dosage</b></h2>
<p><span style="font-weight: 400;">For Zepbound, the current U.S. prescribing information starts at <b>2.5 mg once weekly for 4 weeks</b>, followed by <b>5 mg once weekly</b>. Further increases can be made in <b>2.5 mg increments</b> at intervals of at least 4 weeks, with maintenance doses of <b>5, 10, or 15 mg once weekly</b> depending on indication and tolerability.</span></p>
<h2><b>Side Effects</b></h2>
<p><span style="font-weight: 400;">The most common adverse effects include nausea, diarrhea, vomiting, constipation, and abdominal discomfort. Important warnings include pancreatitis, gallbladder disease, acute kidney injury associated with severe gastrointestinal reactions, and the boxed warning concerning thyroid C-cell tumors observed in rodents.</span></p>
<h3><b>References</b></h3>
<ol>
<li style="font-weight: 400;"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806s002lbl.pdf" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">FDA — current Zepbound (tirzepatide) prescribing information</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=tirzepatide+SURPASS+type+2+diabetes" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Tirzepatide and type 2 diabetes — SURPASS clinical research.</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=tirzepatide+SURMOUNT+obesity" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Tirzepatide and obesity — SURMOUNT clinical research.</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=tirzepatide+cardiovascular+metabolic" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Tirzepatide cardiovascular and metabolic research.</span></a></li>
</ol>
<p><b>Note:</b><span style="font-weight: 400;"> BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.</span></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Semaglutide</title>
		<link>https://behemothlabz.com/product/semaglutide/</link>
		
		<dc:creator><![CDATA[Zeeshan Tariq]]></dc:creator>
		<pubDate>Thu, 01 Oct 2026 17:05:36 +0000</pubDate>
				<guid isPermaLink="false">https://behemothlabz.com/?post_type=product&#038;p=150783</guid>

					<description><![CDATA[Semaglutide is a long-acting GLP-1 receptor agonist with extensive clinical evidence in type 2 diabetes, obesity, cardiovascular risk reduction, and related metabolic conditions.]]></description>
										<content:encoded><![CDATA[<h2><b>Buy Semaglutide Online</b></h2>
<p><span style="font-weight: 400;">Semaglutide is a long-acting <b>GLP-1 receptor agonist</b> with extensive clinical evidence in type 2 diabetes, obesity, cardiovascular risk reduction, and related metabolic conditions.</span></p>
<h2><b>Product Information</b></h2>
<p><span style="font-weight: 400;">Semaglutide is structurally related to human GLP-1 and has approximately <b>94% sequence homology with human GLP-1</b>. It activates GLP-1 receptors involved in glucose-dependent insulin secretion, appetite regulation, gastric emptying, and energy balance.</span></p>
<h2><b>How It Works</b></h2>
<p><span style="font-weight: 400;">Semaglutide activates GLP-1 receptors in the pancreas, brain, gastrointestinal tract, and other tissues. It increases glucose-dependent insulin secretion, reduces glucagon secretion when glucose is elevated, slows gastric emptying, and influences appetite-regulating pathways.</span></p>
<h2><b>POTENTIAL BENEFITS</b></h2>
<h3><b>1. Blood-Glucose Research</b></h3>
<p><span style="font-weight: 400;">Semaglutide has demonstrated clinically meaningful reductions in blood glucose and HbA1c in people with type 2 diabetes. Its glucose-dependent mechanism helps explain its established role in diabetes treatment.</span></p>
<h3><b>2. Weight-Management Research</b></h3>
<p><span style="font-weight: 400;">Large clinical trials have demonstrated substantial body-weight reductions with once-weekly semaglutide alongside lifestyle intervention. The compound is therefore extensively studied in obesity and metabolic research.</span></p>
<h3><b>3. Cardiovascular Research</b></h3>
<p><span style="font-weight: 400;">Semaglutide has been studied in cardiovascular-risk populations, with clinical evidence supporting cardiovascular risk reduction in specified patient groups. Current U.S. labeling includes cardiovascular-risk indications for selected populations.</span></p>
<h3><b>4. Metabolic Research</b></h3>
<p><span style="font-weight: 400;">Beyond weight and glucose, semaglutide has been investigated in areas including cardiovascular disease, kidney outcomes, and metabolic liver disease. Its broad research profile reflects the wide physiological distribution of GLP-1 signaling.</span></p>
<h2><b>Dosage</b></h2>
<p><span style="font-weight: 400;">For the current U.S. injectable Wegovy formulation, treatment is initiated at <b>0.25 mg once weekly for 4 weeks</b>, followed by gradual escalation. The labeled maintenance dosage for most weight-management indications is <b>2.4 mg once weekly</b>, with 1.7 mg available as an alternative maintenance dose in appropriate circumstances.</span></p>
<h2><b>Side Effects</b></h2>
<p><span style="font-weight: 400;">The most common adverse effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Important labeled warnings include acute pancreatitis, gallbladder disease, and the contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN2.</span></p>
<h3><b>References</b></h3>
<ol>
<li style="font-weight: 400;"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf?aid=EN" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">FDA — current Wegovy (semaglutide) prescribing information</span></a></li>
<li style="font-weight: 400;"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s015lbl.pdf" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">FDA — semaglutide formulation and mechanism information</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=semaglutide+cardiovascular+outcomes" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Semaglutide and cardiovascular outcomes — PubMed</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=semaglutide+obesity+STEP+trial" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Semaglutide and obesity clinical trial — PubMed</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=semaglutide+type+2+diabetes+SUSTAIN" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Semaglutide in type 2 diabetes — PubMed</span></a></li>
</ol>
<p><b>Note:</b><span style="font-weight: 400;"> BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.</span></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Telmisartan</title>
		<link>https://behemothlabz.com/product/telmisartan/</link>
		
		<dc:creator><![CDATA[Zeeshan Tariq]]></dc:creator>
		<pubDate>Thu, 01 Oct 2026 17:05:33 +0000</pubDate>
				<guid isPermaLink="false">https://behemothlabz.com/?post_type=product&#038;p=150782</guid>

					<description><![CDATA[Telmisartan is an angiotensin II receptor blocker (ARB) used clinically to treat hypertension and, in appropriate patients, reduce cardiovascular risk. It has also been investigated for metabolic and PPAR-related effects beyond conventional blood-pressure control.]]></description>
										<content:encoded><![CDATA[<h2><b>Buy Telmisartan Online</b></h2>
<p><span style="font-weight: 400;">Telmisartan is an <b>angiotensin II receptor blocker (ARB)</b> used clinically to treat hypertension and, in appropriate patients, reduce cardiovascular risk. It has also been investigated for metabolic and PPAR-related effects beyond conventional blood-pressure control.</span></p>
<h2><b>Product Information</b></h2>
<p><span style="font-weight: 400;">Telmisartan selectively blocks the angiotensin II AT1 receptor, preventing angiotensin II from producing vasoconstriction and aldosterone-related effects. It has a long elimination half-life, supporting once-daily administration in standard clinical use.</span></p>
<h2><b>How It Works</b></h2>
<p><span style="font-weight: 400;">Telmisartan blocks AT1 receptors in the renin-angiotensin system. This reduces vasoconstriction and aldosterone-mediated sodium retention, lowering vascular resistance and blood pressure.</span></p>
<h2><b>POTENTIAL BENEFITS</b></h2>
<h3><b>1. Blood-Pressure Research</b></h3>
<p><span style="font-weight: 400;">Telmisartan is well established as an antihypertensive medication. Controlled clinical studies have demonstrated reductions in blood pressure through blockade of angiotensin II signaling.</span></p>
<h3><b>2. Cardiovascular Research</b></h3>
<p><span style="font-weight: 400;">By reducing blood pressure and blocking AT1 signaling, telmisartan has been studied extensively in cardiovascular-risk populations. Its clinical research extends beyond simple blood-pressure measurements.</span></p>
<h3><b>3. Renin-Angiotensin Research</b></h3>
<p><span style="font-weight: 400;">Telmisartan is an important pharmacological tool for studying the renin-angiotensin-aldosterone system. AT1 receptor blockade allows researchers to examine downstream cardiovascular and renal effects of angiotensin II.</span></p>
<h3><b>4. Metabolic Research</b></h3>
<p><span style="font-weight: 400;">Telmisartan has also attracted interest because of reported interactions with metabolic pathways, including partial PPAR-γ activity. These effects have been investigated separately from its established ARB mechanism.</span></p>
<h2><b>Dosage</b></h2>
<p><span style="font-weight: 400;">For hypertension, the current U.S. labeling lists <b>40 mg once daily</b> as the usual starting dose, with a usual range of <b>40–80 mg once daily</b>. For cardiovascular-risk reduction in the labeled indication, <b>80 mg once daily</b> is specified. Dosage must be individualized according to indication and clinical response.</span></p>
<h2><b>Side Effects</b></h2>
<p><span style="font-weight: 400;">Common concerns include dizziness, hypotension, and changes in kidney function or potassium levels. Telmisartan carries an important pregnancy warning because drugs acting on the renin-angiotensin system can cause fetal injury.</span></p>
<h3><b>References</b></h3>
<ol>
<li style="font-weight: 400;"><a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c22a318-d1f2-4788-9331-66fed71ebf38" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">DailyMed — current Telmisartan prescribing information</span></a></li>
<li style="font-weight: 400;"><a href="https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1a907a7-fad9-a860-8639-4c6136c85734&amp;version=4" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">DailyMed — Telmisartan label and warnings</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=telmisartan+cardiovascular+trial" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Telmisartan cardiovascular outcomes research — PubMed</span></a></li>
<li style="font-weight: 400;"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=telmisartan+PPAR-gamma" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">Telmisartan and PPAR-gamma research — PubMed</span></a></li>
</ol>
<p><b>Note:</b><span style="font-weight: 400;"> BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.</span></p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
